ONL Therapeutics
onltherapeutics.com
Actively hiring
Ophthalmology & Eye Clinics
Biologics & Biosimilars
Health Care
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$106.4M
9 rounds on record
Latest round
$60M
Venture round · Sep 2024 · 2 yr ago
Team
201-500
employees, estimated range
Backers
1
Novartis Venture Fund
The money's age
Due for its next round
24 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 12, 2024
Raised a round Venture round $60M · SEC Form D
Feb 29, 2024
Raised a round Venture round $10M · SEC Form D
Mar 7, 2023
Raised a round Venture round $5M · SEC Form D
Dec 18, 2020
Raised a round Venture round $26.8M · SEC Form D
Oct 19, 2020
Raised a round Convertible Note $2M · SEC Form D
Aug 15, 2019
Took on debt financing $3M · SEC Form D
Sep 7, 2018
Took on debt financing $639k · SEC Form D
May 12, 2017
Raised a round Venture round $2.6M · SEC Form D
Aug 1, 2016
Took on debt financing $916k · SEC Form D
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Sep 2024 | $60M | — | SEC Form D |
| Venture round | Feb 2024 | $10M | — | SEC Form D |
| Venture round | Mar 2023 | $5M | — | SEC Form D |
| Venture round | Dec 2020 | $26.8M | — | SEC Form D |
| Convertible Note | Oct 2020 | $2M | — | SEC Form D |
| Debt Financing | Aug 2019 | $3M | — | SEC Form D |
| Debt Financing | Sep 2018 | $639k | — | SEC Form D |
| Venture round | May 2017 | $2.6M | — | SEC Form D |
| Debt Financing | Aug 2016 | $916k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | ONL Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
John FreshleyExecutive Officer, DirectorSEC Form D
David ZacksExecutive OfficerSEC Form D
David EspositoExecutive Officer, DirectorSEC Form D
Constance ChangExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Novartis Venture Fund Similar startupsby what they do, their industry and backers
HOME GAMES SUPPORT NEWS Customer Service Support News and Blogs Do Not Sell My Personal Information Company About Us Privacy Policy Terms…
Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting…
Diode. DIODE © 2026, All Rights Reserved | Terms | Privacy Policy.
Every Store. One Checkout.. © 2026 Aisle-3 . All rights reserved.
Contact Us. © 2026 Lotas. All rights reserved.
Building the future of trusts.. © 2025 Sava. All rights reserved.
Overview
News. Privacy Statement | Accessibility Statement | Terms of Use | Copyright All Rights Reserved ©2026.
People
John Freshley
Executive Officer, Director
David Zacks
Executive Officer
David Esposito
Executive Officer, Director
Constance Chang
Executive Officer
Loic Couraud
Director
William Brinkerhoff
Director
Mark Hooper
Director
Rafael Castilla
Director
Christine Gibbons
Director
Felicia David-Visser
Director
Bill Burns
Director
Stella Robertson
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Ann Arbor
United States
HQ
200-500 est. staff
Financials
Total raised
$111M
Latest round
Venture - Series Unknown
Funding rounds
9
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2024 | $60M | Details |
| Venture - Series Unknown | 2024 | $10M | Details |
| Venture - Series Unknown | 2023 | $5M | Details |
| Venture - Series Unknown | 2020 | $26.8M | Details |
| Convertible Note | 2020 | $2M | Details |
| Debt Financing | 2019 | $3M | Details |
| Debt Financing | 2018 | $639k | Details |
| Venture - Series Unknown | 2017 | $2.6M | Details |
| Debt Financing | 2016 | $916k | Details |